Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years

Berning P, Fekom M, Ngoya M, Goldstone AH, Dreger P, Montoto S, Finel H, Shumilov E, Chevallier P, Blaise D, Strüssmann T, Carpenter B, Forcade E, Castilla-Llorente C, Trneny M, Ghesquieres H, Capria S, Thieblemont C, Blau IW, Meijer E, Broers AE, Huynh A, Caillot D, Rösler W, Nguyen Quoc S, Bittenbring J, Nagler A, Galimard JE, Glass B, Sureda A, Schmitz N (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 14

Article Number: 106

Journal Issue: 1

DOI: 10.1038/s41408-024-01085-9

Abstract

Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990–1994) to 58 years (2015–2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased from 36 (1990–1994) to 54 (2015–2021) years, with mobilized blood as the primary source post-1998 and reduced intensity conditioning post-2000. Unrelated and mismatched allo-HSCT accounted for 50% and 19% of allo-HSCT in 2015–2021. Three-year overall survival (OS) after auto-HSCT improved from 56% (1990–1994) to 70% (2015–2021), p < 0.001, with a decrease in relapse incidence (RI) from 49% to 38%, while non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS increased from 33% (1990–1999) to 46% (2015–2021) (p < 0.001); 3-year RI remained at 39% and 1-year-NRM decreased to 19% (p < 0.001). Our data reflect advancements over 32 years and >40,000 transplants, providing insights for evaluating emerging DLBCL therapies.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Münster Germany (DE) European Society for Blood and Marrow Transplantation EBMT Netherlands (NL) Erasmus University Medical Center (MC) Netherlands (NL) Centre Hospitalier Universitaire (CHU) de Toulouse France (FR) Centre hospitalier universitaire (CHU) de Dijon Bourgogne France (FR) Pitié-Salpêtrière University Hospital / Hôpital universitaire Pitié-Salpêtrière France (FR) Universitätsklinikum des Saarlandes (UKS) Germany (DE) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) HELIOS Kliniken Germany (DE) Universitat de Barcelona (UB) / University of Barcelona Spain (ES) Ruprecht-Karls-Universität Heidelberg Germany (DE) St Bartholomew's Hospital United Kingdom (GB) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR) Aix-Marseille University / Aix-Marseille Université France (FR) Universitätsklinikum Freiburg Germany (DE) University College London Hospitals (UCLH) United Kingdom (GB) Centre Hospitalier Universitaire de Bordeaux / CHU Bordeaux France (FR) Institut Gustave-Roussy France (FR) Univerzita Karlova v Praze / Charles University in Prague Czech Republic (CZ) Centre Hospitalier Lyon Sud (CHLS) France (FR) Università degli studi "La Sapienza" Italy (IT) Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal France (FR) Charité - Universitätsmedizin Berlin Germany (DE) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra Netherlands (NL)

How to cite

APA:

Berning, P., Fekom, M., Ngoya, M., Goldstone, A.H., Dreger, P., Montoto, S.,... Schmitz, N. (2024). Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years. Blood Cancer Journal, 14(1). https://doi.org/10.1038/s41408-024-01085-9

MLA:

Berning, Philipp, et al. "Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years." Blood Cancer Journal 14.1 (2024).

BibTeX: Download